Efficacy of Crizotinib for Advanced ALK -Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China
ConclusionsALK-rearranged advanced NSCLC patients with baseline brain metastasis can still achieve OS benefits from crizotinib treatment. However, patients with intracranial progression may not obtain a long-term survival benefit from continuation of CBPD.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | China Health | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Study